Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

By J. van Griensven, T. Edwards, X. de Lamballerie, M.G. Semple, P. Gallian, S. Baize, P.W. Horby, H. Raoul, N. Magassouba, A. Antierens, C. Lomas, O. Faye, A.A. Sall, K. Fransen, J. Buyze, R. Ravinetto, P. Tiberghien, Y. Claeys, M. De Crop, L. Lynen, E.I. Bah, P.G. Smith, A. Delamou, A. De Weggheleire, and N. Haba, for the Ebola-Tx Consortium*
A trial of convalescent plasma to treat Ebola shows it is safe but unselected plasma did not significantly reduce mortality. Analysis of antibody levels is planned to look at whether higher levels of antibodies might be more effective. These results, of the EU funded Ebola_Tx trial conducted in Guinea, are now available in the New England Journal of Medicine, along with a second article in Clinical Trials that describes the process for design and analysis of the trial in an emergency setting and as the epidemic evolved.
Back